TrialThe Journal of antimicrobial chemotherapy2022

Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia.

Ignacio Martin-Loeches et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.